Comment
doi: 10.1038/s41569-019-0170-9.
Modulating myosin function to treat hypertrophic cardiomyopathy
Affiliations
- PMID: 30755739
- DOI: 10.1038/s41569-019-0170-9
Item in Clipboard
Comment
Modulating myosin function to treat hypertrophic cardiomyopathy
Nat Rev Cardiol.
2019 Apr.
No abstract available
Comment on
-
Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin.Sci Transl Med. 2019 Jan 23;11(476):eaat1199. doi: 10.1126/scitranslmed.aat1199. Sci Transl Med. 2019. PMID: 30674652 Free PMC article.
Similar articles
-
Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy.N Engl J Med. 1998 Apr 30;338(18):1248-57. doi: 10.1056/NEJM199804303381802. N Engl J Med. 1998. PMID: 9562578
-
Accumulation and assembly of myosin in hypertrophic cardiomyopathy with the 403 Arg to Gln beta-myosin heavy chain mutation.Circ Res. 1992 Dec;71(6):1404-9. doi: 10.1161/01.res.71.6.1404. Circ Res. 1992. PMID: 1423936
-
Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations.J Clin Invest. 1992 Nov;90(5):1666-71. doi: 10.1172/JCI116038. J Clin Invest. 1992. PMID: 1430197 Free PMC article.
-
Enhanced myosin function due to a point mutation causing a familial hypertrophic cardiomyopathy.Circ Res. 2000 Apr 14;86(7):720-2. doi: 10.1161/01.res.86.7.720. Circ Res. 2000. PMID: 10764403 Review. No abstract available.
-
Molecular basis of hypertrophic and dilated cardiomyopathy.Tex Heart Inst J. 1994;21(1):6-15. Tex Heart Inst J. 1994. PMID: 8180512 Free PMC article. Review.
Cited by
-
New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy.Cardiovasc Hematol Agents Med Chem. 2023;21(2):78-83. doi: 10.2174/1871525721666221019095218. Cardiovasc Hematol Agents Med Chem. 2023. PMID: 36278454 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
